Canada · Delayed Price · Currency is CAD Sun Life Financial Earnings Call Transcripts
Fiscal Year 2026
-
Medium-term targets include 10% earnings growth and 20%+ ROE, with strong progress in asset management and Asia. U.S. stop-loss remains resilient, while dental shifts focus to commercial segments. Asset management integration and a management equity plan aim to drive growth, and capital allocation favors organic expansion and sustainable buybacks.
-
Strong Q2 2026 results featured double-digit EPS growth, robust insurance and asset management sales, and record performance in Canada, Asia, and the U.S. Capital position remains strong, with disciplined execution and strategic investments supporting sustainable growth.
-
Q1 2026 saw solid underlying earnings, strong insurance sales growth in Asia and the U.S., and continued asset management expansion. Capital strength remains high despite acquisition-driven LICAT decline, with a dividend increase and renewed buyback reflecting robust cash flow.
-
Earnings per share grew 12% and ROE surpassed 18%, driven by leadership changes and strong regional performance. U.S. dental strategy shifts to optimizing state business and expanding commercial, while Stop-Loss benefits from pricing power. Asset management focuses on organic growth and targeted bolt-ons.
Fiscal Year 2025
-
Q4 2025 saw double-digit earnings growth, strong sales across all regions, and robust capital generation, with underlying net income up 13% year-over-year and a LICAT ratio of 157%. SLC Management exceeded targets, U.S. stop-loss and dental showed improvement, and digital initiatives drove client engagement.
-
Strategic priorities include asset management integration, U.S. dental business improvement, and digital transformation. Strong capital generation supports disciplined M&A and buybacks, with a focus on achieving a 20% ROE target. Asset management and Asian growth drive outperformance.
-
Q3 2025 saw strong earnings growth in Asia, Canada, and asset management, offset by U.S. headwinds from higher claims and pricing lags. Capital position remains robust with a higher dividend and continued share buybacks. U.S. business recovery is expected as repricing and cost actions take effect.
-
A diversified business mix focused on low-capital group benefits and asset management supports a 20% ROE target. U.S. dental faces short-term headwinds, while asset management and Asia drive growth. Strong capital enables flexibility for buybacks and selective M&A.
-
Q2 2025 saw underlying EPS rise 4% and net income top $1 billion, with strong results in Asia, Canada, and U.S. employee benefits. U.S. dental earnings outlook was revised down due to Medicaid uncertainty, but long-term growth targets remain intact.
-
Record Q1 results with underlying net income up 19% year-over-year and strong growth across all segments. Capital position remains robust, supporting a 5% dividend increase and renewed share buybacks. Asset management, Asia, and Canada led performance, while U.S. and dental segments stabilized.
-
Leadership emphasized strategic pivots, strong culture, and disciplined capital deployment. U.S. group business faces manageable risks, with repricing underway to address claim severity. Asset management growth is driven by upcoming buyouts and platform integration, while surplus assets are being repositioned for better yields.
Fiscal Year 2024
-
Q4 underlying earnings were solid in Canada, Asia, and asset management, but U.S. results were impacted by higher stop-loss claim severity. Full-year underlying net income rose 3% to CAD 3.9 billion, with strong capital and record AUM. Pricing actions and expense efficiencies are expected to support future margins.
-
Raised medium-term targets to 10%+ EPS growth and 20%+ ROE, driven by a diversified, capital-light business mix and strong asset management and digital capabilities. Regional businesses in Canada, the U.S., and Asia each have ambitious growth plans, while digital and GenAI initiatives underpin efficiency and client impact.
-
Q3 2024 saw double-digit EPS growth, record AUM, and robust capital generation, with strong results across all business segments. Strategic investments, disciplined capital allocation, and digital innovation supported growth, while repricing and management actions are expected to drive further improvement in U.S. dental earnings.
-
Q2 delivered a strong rebound with high-quality earnings, robust growth in Canada and Asia, and resilient U.S. performance outside dental, which faces temporary Medicaid challenges. Asset management and alternatives remain strategic priorities, with capital strength supporting buybacks and future investments.
-
Delivered record underlying net income of CAD 1 billion, up 9% year-over-year, with strong growth in individual protection and wealth management. U.S. Dental headwinds persist but recovery is expected by 2025, while restructuring aims for CAD 200 million in savings by 2026.